Moupali Das, MD, MPH
@drmoupali
Followers
2K
Following
37K
Media
169
Statuses
30K
San Francisco
Joined June 2013
An honor to contribute to developing new PrEP options and providing new choices for people disproportionately affected by HIV and historically underrepresented in PrEP studies. #aids2022 #prep #communityengagement
The role of PrEP medicines is pivotal in helping to end the #HIV epidemic. We strive to work with partners to advance research efforts that acknowledge the needs of those disproportionately impacted by HIV and historically underrepresented in PrEP studies. #AIDS2022
5
4
7
JUST ADDED: 12/1, World AIDS Day, join us for an expert panel exploring "Are We Winning the Fight?" Learn about cutting-edge research & drug development. Hear from @drmoupali @MonicaGandhi9 @Dr_NassMohamed & Demetre C. Daskalakis Free. Details & tickets: https://t.co/hYlYT0b7ZX
0
4
4
#GileadNews: Gilead joined partners in delivering the first shipments of our twice-yearly HIV prevention option to Eswatini & Zambia, an important milestone in our shared efforts to accelerate progress toward ending the HIV epidemic in sub-Saharan Africa. https://t.co/4O2TSgvUDg
0
3
8
@GileadSciences @Georgetown @drmoupali During the Q&A, @drmoupali and Dr. @CharlesBHolmes addressed audience questions ranging from how lessons learned from COVID-19 informed Gilead’s approach to lenacapavir, to how the PURPOSE program is navigating cultural barriers to treatment access.
1
1
1
@GileadSciences @Georgetown .@drmoupali speaks on inclusive efforts to make sure the Purpose programs represented and benefited the most disproportionately impacted communities.
1
1
1
The CDC officially recommends Yeztugo (lenacapavir), @GileadSciences' long-acting injectable form of pre-exposure prophylaxis, or PrEP, for people at risk of HIV. In clinical trials, the injection, given every six months, all but eliminated new cases of HIV. "Lenacapavir,
3
2
6
#GileadNews: @CDCgov has released new guidelines for our twice-yearly #HIV prevention medication. This is an important milestone as we strive to help transform HIV prevention in the U.S. More: https://t.co/wFK4atsmHA
4
16
28
5/ That inclusion was no accident. Dr. Moupali Das, head of HIV prevention at Gilead, led the trial with a focus on equity—centering women from the start, not as an afterthought.
1
2
5
Lenacapavir was recently approved by the FDA, marking a milestone in the decades-long fight to end the HIV epidemic. Three individual who were instrumental in developing the drug were honored last month with the AAAS Mani L. Bhaumik Breakthrough of the Year Award.
0
2
5
#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. https://t.co/wGacaduPRn
0
89
139
This annual shot might protect against HIV infections
technologyreview.com
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
2
4
10
#MedTwitter I’ve joined Bluesky. @drmoupali.bsky.social Let’s connect there!
0
0
0
ICYMI: Dr. @drmoupali presented data at #CROI2025 showing @GileadSciences's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. The phase 1 study paves the way for improved adherence & HIV prevention @CROI_Official @TheLancet
https://t.co/Deh7VzJShH
0
1
1
#GileadNews: Today at #CROI2025, we announced initial data about our investigational once-yearly medication for HIV prevention. This is part of our mission to continue to innovate new person-centered #HIV prevention options. Learn more: https://t.co/ofTpTuLQaW
0
18
38
Dr. @drmoupali from @GileadSciences presented their Phase 1 results on once-yearly intramuscular lenacapavir for #HIVprevention. Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 @CROI_Official
https://t.co/Deh7VzKq7f
contagionlive.com
New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
0
2
5
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. Learn more about this year's #BOTY and other big advances in science: https://t.co/jSp6Bofv4o
54
179
543
HAPPENING NOW! AVAC's executive director Mitchell Warren kicks off today's webinar where we'll dive into the latest updates in the PURPOSE trials and what's next for #lenacapavir, the twice-yearly injectable #PrEP. Follow this 🧵 for live updates from the meeting.
Join AVAC tomorrow at 10:30AM ET as we hear updates on the two PURPOSE trials and what's next for lenacapavir from Gilead and joined by civil society and advocates in the prevention field. Register and learn more here! https://t.co/2bf3LpI7EA
1
3
12
Gilead’s @drmoupali recognizes the importance of community engagement: “Thank you to AVAC for all the work that you’ve done to work with advocates to help educate and train people to engage in clinical trials. We could not have done this program without the larger community.”
1
1
2
Game-changer for HIV prevention! The twice-yearly injection of lenacapavir showed a 96% reduction in HIV infections in the PURPOSE 2 trial. Source: @EmoryUniversity News Center, Nov. 27, 2024
1
1
1
#Lenacapavir “This is a considerable and profound advancement in medicine, especially for people whose circumstances don’t allow them to take a daily oral medication, and for those among populations disproportionately impacted by #HIV.” @colleenfkelley
https://t.co/dNrQyxYddi…
0
1
1
Today, on World AIDS Day, Unitaid highlights lenacapavir—a powerful tool to help end HIV as a public health threat. We are actively working to ensure it reaches those most at risk, as quickly as possible. Together, we can make this a reality. Learn more: https://t.co/wx37t5ak34
0
6
8